Lisata Therapeutics, Inc. (LSTA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company developing certepetide, an investigational drug designed to enhance the delivery of anti-cancer therapies to solid tumors. This report covers the quarterly period ended June 30, 2025. The company operates as a single segment focused on research and development. As of June 30, 2025, the company had 8,626,464 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $70 | $0 | $70 | $0 |
| Net Loss | $(4,659) | $(5,044) | $(9,383) | $(10,445) |
| Operating Expenses | $4,938 | $5,523 | $10,786 | $12,124 |
| Cash & Cash Equivalents | $16,835 | $22,593 (End of Period) | $16,835 | $28,293 (End of Period) |
| Marketable Securities | $5,135 | $15,036 (End of Period) | $5,135 | $15,036 (End of Period) |
| Total Liquidity (Cash + Securities) | $21,970 | $37,629 | $21,970 | $43,329 |
| Working Capital | $20,572 | $28,965 | $20,572 | $28,965 |
Note: Revenue of $70,000 for the period ended June 30, 2025, relates to an upfront license fee from a research collaboration. The company reported a benefit from income taxes of $962,000 for the six months ended June 30, 2025, primarily due to the sale of New Jersey net operating losses.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 10.6% ($585,000) in Q2 2025 compared to Q2 2024. Research and Development (R&D) expenses dropped 13.4% due to reduced patient treatment costs and lower spend on chemistry, manufacturing, and controls (CMC). General and Administrative (G&A) expenses decreased 8.1% due to workforce reductions and lower consulting/travel costs.
- Liquidity Position: Total cash and marketable securities decreased from approximately $37.6 million at June 30, 2024, to $22.0 million at June 30, 2025. This reduction is attributed to operating cash burn and net purchases of marketable securities, partially offset by net sales of securities.
- Revenue Recognition: The company recognized $70,000 in revenue in Q2 2025, whereas no revenue was recognized in the same period in 2024.
- Investment Income: Investment income decreased from $493,000 in Q2 2024 to $216,000 in Q2 2025, reflecting lower interest rates and reduced marketable securities balances.
Outlook, Guidance, and Risks
- Liquidity Outlook: Management believes current cash and marketable securities ($22.0 million) are sufficient to fund operations for at least the next 12 months. The company anticipates needing additional financing by the fourth quarter of 2026 to meet long-term needs.
- Operational Adjustments: To preserve capital, the company has placed the FORTIFIDE study on hold and delayed certain Phase 3 readiness activities related to CMC. Ongoing trials, including the ASCEND trial for metastatic pancreatic cancer, continue as planned.
- Clinical Progress: Preliminary data from the ASCEND trial (Cohort B) presented in July 2025 showed clinically meaningful improvements in progression-free survival and objective response rates for patients treated with certepetide plus standard-of-care chemotherapy compared to placebo.
- Risks: Key risks include the ability to secure sufficient capital, the success of clinical trials, regulatory approvals, and the potential for dilution from future equity issuances. The company is subject to the "Baby Shelf Limitation" on its At-The-Market (ATM) offering program due to its public float being below $75 million.
- Subsequent Events: On July 15, 2025, the company received a U.S. patent (No. 12,351,653) covering the composition of matter of certepetide, expiring in March 2040.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $22.0 million liquidity position against the projected burn rate, considering the delay of the FORTIFIDE study and CMC activities.
- ASCEND Trial Data: Review the full data release from the ASCEND trial (Cohorts A and B) expected later in 2025 to confirm the statistical significance of the preliminary results.
- Financing Needs: Monitor announcements regarding the need for additional capital by Q4 2026 and the potential impact of the "Baby Shelf Limitation" on the company's ability to raise funds via its ATM program.
- License Agreements: Track the status of the Qilu Pharmaceutical agreement (China) and the new Kuva Labs agreement, specifically regarding milestone payments and royalty triggers.
- Patent Portfolio: Assess the strategic value of the newly granted U.S. patent for certepetide and its impact on the company's intellectual property moat.